Kommentar – Die Messlatte für Tumortherapeutika höher legen …

• 1 Ellis LM, Bernstein DS, Voest EE et al. American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes. 2014; 17 (ahead of print)
• 2 Dilts D. Time Has Come to Raise the Bar in Oncology Clinical Trials. JCO 2014; 17 (ahead of print)
• 3 Deisseroth A, Kaminskas E, Grillo J et al. U.S. Food and Drug Administration approval: Ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. 2012; 18: 3212-3217
• 4 Dorman S, Hayes J. What do patients with brain metastases from non-small cell lung cancer from their treatment?. Pall Med 2009; 23: 594-600
• 5 Cella D, Vervölgyi V, Wörmann B. Neue Medikamente in der Onkologie: Nutzen, Risiken und Herausforderungen. Onkologie 2013; 36 (Suppl. 05) 12-19
• 6 Siegmund-Schulze N. „Die Messlatte höher legen“. Dt. Ärzteblatt 2014; 111: B551